Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Eluxadoline: a promising therapy that raises many questions.

Literature DB >> 28138642

Eluxadoline: a promising therapy that raises many questions.

Brooks D Cash¹.

Abstract

Entities: Chemical

Year: 2016 PMID： 28138642 PMCID： PMC5244598 DOI： 10.21037/tgh.2016.09.06

Source DB: PubMed Journal: Transl Gastroenterol Hepatol ISSN： 2415-1289

× No keyword cloud information.

17 in total

Review 1. An evidence-based position statement on the management of irritable bowel syndrome.

Authors: Lawrence J Brandt; William D Chey; Amy E Foxx-Orenstein; Lawrence R Schiller; Philip S Schoenfeld; Brennan M Spiegel; Nicholas J Talley; Eamonn M M Quigley
Journal: Am J Gastroenterol Date: 2009-01 Impact factor: 10.864

2. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.

Authors: M Pimentel; E J Chow; H C Lin
Journal: Am J Gastroenterol Date: 2000-12 Impact factor: 10.864

3. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.

Authors: Anthony J Lembo; Brian E Lacy; Marc J Zuckerman; Ron Schey; Leonard S Dove; David A Andrae; J Michael Davenport; Gail McIntyre; Rocio Lopez; Lisa Turner; Paul S Covington
Journal: N Engl J Med Date: 2016-01-21 Impact factor: 91.245

4. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts.

Authors: Brennan M R Spiegel; Mary Farid; Eric Esrailian; Jennifer Talley; Lin Chang
Journal: Am J Gastroenterol Date: 2010-03-02 Impact factor: 10.864

Review 5. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life.

Authors: Hashem B El-Serag
Journal: Rev Gastroenterol Disord Date: 2003

Review 6. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.

Authors: Uday C Ghoshal; Deepakshi Srivastava
Journal: World J Gastroenterol Date: 2014-03-14 Impact factor: 5.742

Review 7. Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care--a Rome Foundation working team report.

Authors: A P S Hungin; M Molloy-Bland; R Claes; J Heidelbaugh; W E Cayley; J Muris; B Seifert; G Rubin; N de Wit
Journal: Aliment Pharmacol Ther Date: 2014-09-17 Impact factor: 8.171

Eluxadoline: a promising therapy that raises many questions.

Review 1. An evidence-based position statement on the management of irritable bowel syndrome.

2. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.

3. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.

4. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts.

Review 5. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life.

Review 6. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.

Review 7. Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care--a Rome Foundation working team report.

8. Targeted therapies for diarrhea-predominant irritable bowel syndrome.

9. Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.

Review 10. The epidemiology of irritable bowel syndrome.

Review 1. Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Review 2. Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy.